Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies.

By M. Heinrich, C. Blanke, Brian J. Druker, Christopher Corless. Journal of Clinical Oncology, 2002

672 citations recorded by the source corpus.

Subfields: Gastroenterology, Hematology, Immunology

View Paper: https://www.semanticscholar.org/paper/4d07d7cad03debcf6d3a632bb1efdc1aa1d7eb2a

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. T. Abrams
2. Leslie B. Lee
3. D. Mendel
4. Lesley J. Murray
5. A. Laird
6. T. J. Ngai
7. C. Tang
8. E. Chan

Citations in the corpus

• Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. (2003, neutral): “Symptom improvement rate [95% CI] 44 (43) [33-53] 40 (35) [26-45] 84 (39) [32-45] .”
• In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. (2003, background): “KIT juxtamembrane mutation in gastrointestinal stromal tumors and collagen IA1/PDGF-B fusions in dermatofibrosarcoma protuberans) (4, 5).”
• Gastrointestinal stromal tumors: The incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era (2005, neutral): “5); Int: 55 (19); H: 60 (21); OM: 29 (10)”